Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$334.87 0.00 (0.00)%
Market Cap 0.00M
03/21/18 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)Read on
Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver DiseaseRead on
Regeneron/Sanofi Investor Call at ACC (Orlando, FL March 10, 2018)
Mar 10, 2018 | 12:00 PM ET
Mar 10, 2018 | 9:00 AM ET